In contrast to similar reviews, for example, here we conducted a more detailed analytical work, which included not just a description of Pink1 and Parkin and currently available therapeutic developments, but also an analysis of the consideration of Pink1 and Parkin as therapeutic targets based on their properties, as well as an analysis of the prospects for the development of mitophagy protein activators for the treatment of PD [59]. This evidence concerns the gene PINK1 and Parkinson disease.